Portal de Periódicos da CAPES

Chelates of gadolinium and dysprosium as contrast agents for MR imaging

1993; Wiley; Volume: 3; Issue: 1 Linguagem: Inglês

10.1002/jmri.1880030129

1522-2586

Scott M. Rocklage, Alan D. Watson,

Advanced MRI Techniques and Applications

Journal of Magnetic Resonance ImagingVolume 3, Issue 1 p. 167-178 Review Chelates of gadolinium and dysprosium as contrast agents for MR imaging Scott M. Rocklage PhD, Corresponding Author Scott M. Rocklage PhD Nycomed Salutar Inc, 428 Oakmead Parkway, Sunnyvale, CA 94086Nycomed Salutar Inc. 428 Oakmead Parkway, Sunnyvale, CA 94086Search for more papers by this authorAlan D. Watson PhD, Alan D. Watson PhD Nycomed Salutar Inc, 428 Oakmead Parkway, Sunnyvale, CA 94086Search for more papers by this author Scott M. Rocklage PhD, Corresponding Author Scott M. Rocklage PhD Nycomed Salutar Inc, 428 Oakmead Parkway, Sunnyvale, CA 94086Nycomed Salutar Inc. 428 Oakmead Parkway, Sunnyvale, CA 94086Search for more papers by this authorAlan D. Watson PhD, Alan D. Watson PhD Nycomed Salutar Inc, 428 Oakmead Parkway, Sunnyvale, CA 94086Search for more papers by this author First published: January/February 1993 https://doi.org/10.1002/jmri.1880030129Citations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Bloch F Nuclear induction. Phys Rev 1946; 70: 460–477. 2 Solomon I Relaxation processes in a system of two spins. Phys Rev 1955; 99: 559–565. 3 Bloembergen N Proton relaxation times in paramagnetic solutions. J Chem Phys 1957; 27: 572–581. 4 Horrocks WD. Taylor RC, La Mar GN Isotropic proton magnetic resonance shift in π-bonding ligands coordinated to paramagnetic nickel(II) and cobalt(II) acetylaceto-nates. J Am Chem Soc 1964; 86: 3031–3038. 5 Horrocks WD, Sipe JP Lanthanide complexes as nuclear magnetic resonance structural probes: paramagnetic anisotropy of shift reagent adducts. Science 1972; 93: 994–996. 6 Horrocks WD. Sipe JP Lanthanide shift reagents: a survey. J Am Chem Soc 1971; 93: 6800–6804. 7 Hinckley CC Paramagnetic shifts in solutions of cholesterol and the dipyridine adduct of trisdipivalomethana-toeuropium(III): a shift reagent. J Am Chem Soc 1969; 91: 5160–5162. 8 Barry CD, Glasel JA, Williams RJP, Xavier AV Quantitative determination of conformations of flexible molecules in solution using lanthanide ions as nuclear magnetic resonance probes: application to adenosine-5′-monophos-phate. J Mol Biol 1974; 84: 471–490. 9 Dechter JJ, Levy GC Aqueous relaxation reagents in nitrogen-15 NMR. J Magn Reson 1980; 39: 207–215. 10 Lauterbur PC Image formation by induced local interactions: examples employing nuclear magnetic resonance. Nature 1973; 242: 190–191. 11 Lauterbur PC, Dias MH Mendonca, Rudin AM Augmentation of tissue water proton spin-lattice relaxation rates by the in vivo addition of paramagnetic ions. In: PC Duton, ed. Frontiers of biological energetics. New York, NY: Academic Press, 1978; 752–759. 12 Goldman MR, Brady TJ, Pykett IL, et al. Quantification of experimental myocardial infarction using nuclear magnetic resonance imaging and paramagnetic ion contrast enhancement in excised canine hearts. Circulation 1982; 66: 1012–1016. 13 Lauterbur PC. Jacobsen MJ, Rudin AM, Glucksman MJ, Dias MH Mendonca Water proton relaxation by manga-nous ion in tissues (abstr). Presented at the 19th Experimental Nuclear Magnetic Resonance Conference, Blacks-burg, Va, April 16–20, 1978. 14 Lauterbur PC Progress in NMR zeugmatographic imaging. Philos Trans R Soc Lond [Biol] 1980; 289: 483–487. 15 Lauterbur PC, Dias MH Mendonca, Rudin AM, Glucksman MJ Biomedical imaging by NMR zeugmatography: the use of magnetic relaxation agents (abstr). Presented at the Sixth International Biophysics Congress, Kyoto [Japan], Symposium, September 3–9, 1978. 16 Carr DH, Brown J, Bydder GM, et al. Intravenous che-lated gadolinium as a contrast agent in NMR imaging of cerebral tumors. Lancet 1984; 1: 484–486. 17 Dobson CM, Williams RJP, Xavier AV Ethylenediamine-tetraacetatolanthanate(III), -praesodimate(III), -europa-te(III), and -gadolinate(III) complexes as nuclear magnetic resonance probes of the molecular conformations of adenosine 5′-monophosphate and cytidine 5′-monophos- phate in solution. J Chem Soc Dalton Trans 1974; 1762–1764. 18 Weinmann HJ, Brasch RC, Press WR, Wesbey GE Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 1984; 42: 619–624. 19 Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR 1984; 143: 215–224 20 Laniado M, Weinmann JH, Schorner W, Felix R, Speck V First use of GdDTPA/dimeglumine in man. Physiol Chem Phys Med NMR 1984; 16: 157–165. 21 Young IR, Clark GJ, Bailes DR, Pennock JM, Doyle FH, Byder GM Enhancement of relaxation rate with paramagnetic contrast agents in NMR imaging. J Comput Assist Tomogr 1981; 5: 543–546. 22 Wesbey GE, Brasch RC, Engelstad BL, Moss AA, Crooks LE, Brito AC Nuclear magnetic resonance contrast enhancement study of the gastrointestinal tract of rats and a human volunteer using nontoxic oral iron solutions. Radiology 1983; 149: 175–180. 23 Atkins HL, Som P, Fairchild RG, et al. Myocardial positron tomography with manganese-52m. Radiology 1979; 133: 769–774. 24 Cotzias GC Manganese in health and disease. Physiol Rev 1958; 38: 503–532. 25 Huang CC, Chu NS, Lu CS, et al. Chronic manganese intoxication. Arch Neurol 1989; 46: 1104–1106. 26 Haley TJ Toxicity. In: KA Gschweider, L Eyring, eds. Handbook on the physics and chemistry of rare earths. Amsterdam, The Netherlands: North Holland, 1979; 565–576. 27 Haley TJ Pharmacology and toxicology of the rare earth elements. J Pharm Sci 1965; 54: 663–670. 28 Cacheris WP, Quay SC, Rocklage SM The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8: 467–481. 29 Spencer H, Rosoff B Removal of scandium-46 in man. Health Phys 1965; 11: 1181–1185. 30 Rosoff B, Siegel E, Williams GL, Spencer H Distribution and excretion of radioactive rare earth compounds in mice. Int J Appl Radial Isotopes 1963; 14: 129–135. 31 Engelstad BL, Ramos EC, Macapinlac HA, Johnson TR, White DL, Moseley ME Fe-HBED and Fe-EHPG: iron complexes exhibiting hepatobiliary enhancement in MRI. Clin Nucl Med 1986; 11: 19. 32 Wilson LJ, Lee DW Considerations involving paramagnetic coordination compounds as useful NMR contrast agents. Int J Radiat Appl Instrum (Br) 1988; 15: 31–36. 33 Martell AE The design and synthesis of chelating agents. In: AE Martell, WF Anderson, DG Badman eds. Development of iron chelators for clinical use. New York, NY: Elsevier/North Holland, 1981; 67–104. 34 Connors KA Binding constants. New York, NY: Wiley, 1987. 35 DJ Legget, ed: Computational methods for the determination of formation constants. New York, NY: Plenum, 1985. 36 Bersworth FC Aliphatic polycarboxylic amino acids and methods for making them. U.S. patent 2,407,645, 1946. 37 Durham EJ, Ryskiewich DP The acid dissociation constants of DTPA and the stability constants of some of its metal chelates. J Am Chem Soc 1958; 80: 4812–4817. 38 Frost AE Polyaminopolycarboxylic acids derived from polyethyleneamines. Nature 1956; 178: 322. 39 Harder R, Chaberek S The interaction of rare earth ions with diethylenetriaminepentaacetic acid. J Inorg Nucl Chem 1959; 11: 197–209. 40 Belknap EL EDTA in the treatment of lead poisoning. Ind Med Surg 1952; 21: 305–306. 41 Gries H, Rosenberg D, Weinmann HJ Diagnostic media. U.S. patent 4,647,447, 1987. 42 Gries H, Rosenberg D, Weinmann HJ German patent DE 3129906, 1981. 43 Sinha SP Structure and bonding in highly coordinated lanthanide complexes. Struct Bonding 1976; 45: 69–149. 44 Williams RJP The chemistry of lanthanide ions in solu-tion and in biological systems. Struct Bonding 1982; 50: 79–119. 45 Gries H, Miklautz H Some physicochemical properties of the gadolinium-DTPA complex, a contrast agent for MRI. Physiol Chem Phys Med NMR 1984; 16: 105–112. 46 Stezowski JJ, Hoard JL Heavy metal ionophores: correlations among structural parameters of complexed non-peptide polyamino acids. Isr J Chem 1984; 24: 323–334. 47 Ehnebom E, Pedersen BF Molecular and crystal structure of a lanthanide complex, DyDTPA-BMA hydrate. Acta Chem Scand 1992; 46: 126–130. 48 Watson A Preclinical development of a new susceptibility-based magnetic resonance contrast agent for perfusion-sensitive imaging (in press). 49 Muller RN, Vallet P, Maton F, et al. Recent developments in design, characterization, and understanding of MRI and MRS contrast media. Invest Radiol 1990; 25 (suppl): S34–S36. 50 Bauer RO, Rullo FR, Spooner C, Woodman D Acute and subacute toxicity of ethylenediaminetetraacetic acid (EDTA) salts. Fed Proc 1952; 11: 321. 51 Rubin M, Gignac S, Bessman SP, Belknap EL Enhancement of lead excretion in humans by disodium calcium ethylenediamine tetraacetate. Science 1953; 117: 659–660. 52 Wedeking P, Tweedle M Comparison of the biodistribu-tion of 153Gd-labeled Gd(DTPA)2−, Gd(DOTA)− and Gd(ac-etate) in mice. Int J Radiat Appl Instrum (Br) 1988; 15: 395–402. 53 Weinmann HJ, Laniado M, Mützel W Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1988; 16: 167–172. 54 Täber U, Weinmann HJ, Panzer M, Acksteiner B, Vollert B, Schulze PE Whole-body autoradiographic studies in rats with gadolinium diethylenetriaminepentaacetic acid, a new contrast agent for magnetic resonance imaging. Arzneim-Forsch 1986; 36: 1089–1091. 55 Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B Gd-DOTA: pharmacokinetics and tolera-bility after intravenous injection into healthy volunteers. Invest Radiol 1990; 25: 933–937. 56 Soltys R Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992; 27 (suppl): S7–S11. 57 McLachlan SJ, Eaton S, DeSimone DN Pharmacokl-netic behavior of gadoteridol injection. Invest Radiol 1992; 27 (suppl): S12–S15. 58 Van Wagoner M, O'Toole M, Worah D, Leese PT, Quay SC A phase I clinical trial with gadodiamide injection, a non-ionic MRI enhancement agent. Invest Radiol 1991; 26: 980–986. 59 Wedeking P, Kumar K, Tweedle MF Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992; 10: 641–648. 60 Saini S, Stark DD, Brady TJ, Wittenberg J, Ferrucci JT Dynamic spin-echo MRI of liver cancer using gadolinium-DTPA: animal investigation. AJR 1986; 147: 357–362. 61 Quay SC Diamide-DTPA-paramagnetic contrast agents for MR imaging. U.S. patent 4,687,659, 1987. 62 Quay SC Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging. U.S. patent 4,687,658, 1987. 63 Gries H, Platzek B, Radüchel B, Renneke FJ, Weinmann HJ Low osmolar metal complexes as extracellular contrast media for MRI (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1990. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1990; 737. 64 White DH, Rajagopalan R, Kuan KT, et al. Synthesis and characterization of nonionic paramagnetic metal complexes as potential magnetic resonance imaging contrast agents. Invest Radiol 1990; 25 (suppl): S56–S57. 65 Ball RA, Van Gelder G, Green JW, Reece WO Neoplastic sequelae following subcutaneous implantation of mice with rare earth metals. Proc Soc Exp Biol Med 1970; 135: 426–430. 66 Felder E, Fumagalli L, Uggeri F, Vittadini G Paramagnetic chelates. European patent 0/230/893, 1987. 67 Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiol-ogy 1990; 176: 61–64. 68 Cavagna F, Tirone P, Felder E, De Haën C Hepatobiliary contrast agents for MRI. In: JT Ferrucci, DD Stark, eds. Liver imaging: current trends and new techniques. Boston, Mass: Andover Medical, 1990; 384–393. 69 Vittadini G, Felder E, Tirone P, Lorusso V B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988; 23 (suppl): S246–S248. 70 Cavagna F, Tirone P, Felder E, De Haën C Gd-BOPTA/ dimeg, a new hepatobiliary contrast agent for magnetic resonance imaging. Second European Workshop on Magnetic Resonance in Medicine, Bordeaux, France, 1991; 83–94. 71 Cavagna F, Tirone P, Felder E, De Haen C Hepatobiliary contrast agents for MRI. In: JT Ferrucci, DD Stark, eds. Liver imaging: current trends and new techniques. Boston: Medical Publishers, 1991; 384–393. 72 Vogel TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine-a new contrast agent for MRI: preliminary evaluation in healthy volunteers. AJR 1992; 158: 887–892. 73 Clément O, Mühler A, Vexler A, Berthezene Y, Brasch RC Gadolinium-ethoxybenzyl-DTPA, a new liver-specific MR contrast agent. Invest Radiol 1992; 27: 612–619. 74 Schuhmann-Giampieri G, Schmitt-Willich H, Press W, Negishi C, Weinmann H, Speck U Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59–64. 75 Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 1988; 6: 164–174. 76 Moseley ME, Kucharczyk J, Kurhanewicz J, et al. Early detecting of perfusion deficits induced by regional cerebral ischemia in cats: T2-weighted magnetic susceptibility MRI using a non-ionic dysprosium contrast agent (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1989. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1989; 43. 77 Saeed M, Wendland MF, Tomei E, et al. Demarcation of myocardial ischemia: magnetic susceptibility effect of contrast medium in MR imaging. Radiology 1989; 173: 763–767. 78 Rosen BR, Belliveau JW, Vevea JM, Brady TJ Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14: 249–265. 79 Rosen BR, Belliveau JW, Chien D Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 1989; 5: 263–281. 80 Desreux JF, Merciny E, Loncin MF Nuclear magnetic resonance and potentiometric studies of the protonation scheme of two tetraaza tetraacetic macrocycles. Inorg Chem 1981; 20: 987–991. 81 Stetter HS, Frank W Complex formation with tetraaza-cyclo-alkane-N, N', N', N'-tetraacetic acid as a function of ring size. Angew Chem Int Ed Engl 1976; 15: 686. 82 Clay RM, Corr S, Micheloni M, Paoletti P Noncyclic reference ligands for tetraaza macrocycles: synthesis and theirmodynamic properties of a series of α, ω-di-N-methyl-ated tetraaza ligands and their copper(II) complexes. Inorg Chem 1985; 24: 3330–3336. 83 Desreux JF, Bartholmy PP Highly stable lanthanide macrocyclic complexes: in search of new contrast agents for NMR imaging. Int J Radiat Appl Instrum (Br) 1988; 15: 9–15. 84 Desreux JF, Loncin MF NMR investigation of the lanthanide complexes with a 14-membered polyaza polyace-tic macrocycle, TETA: another rare example of nonlabile lanthanide compounds. Inorg Chem 1986; 25: 69–74. 85 Brucher E, Sherry AD Kinetics of formation and dissociation of the 1,4,7-triazacyclononane-N, N', N'-triacetate complexes of cerium(III), gadolinium(III) and erbium (III) ions. Inorg Chem 1990; 29: 1555–1559. 86 Spirlet MR, Rebizant J, Desreux JF, Loncin MF Crystal and molecular structure of sodium aquo(1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetato)europate(III) tet-rahydrate, Na+ (EuDOTA. H2O)−. 4H2O, and its relevance to NMR studies of the conformational behavior of the lanthanide complexes formed by the macrocyclic li-gand DOTA. Inorg Chem 1984; 23: 359–363. 87 Tweedle MF, Eaton SM, Eckelman WC, et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 1988; 23 (suppl): S236–S239. 88 Mgerstädt M, Gansow OA, Brechbiel MW, et al. Gd(DOTA): an alternative to Gd(DTPA) as a T1.2 relaxation agent for NMR imaging or spectroscopy. Magn Reson Med 1986; 3: 808–812. 89 Meyer D, Schaefer M, Bonnemain B Gd-DOTA, a potential MRI contrast agent: current status of physicochemical knowledge. Invest Radiol 1988; 23 (suppl): S232–S235. 90 Meyer D, Schaefer M, Doucet D Advances in macrocyclic gadolinium complexes as MRI contrast agents (abstr). Presented at the European Congress of Nuclear Magnetic Resonance in Medicine and Biology, Strasbourg, Germany, May 2–5, 1990. 91 Doucet D. Meyer D, Bonnamain B, Doyon D, Caillë JM Gd DOTA. In: VM Runge, ed. Enhanced magnetic resonance imaging 1989 St Louis, Mo: Mosby, 1989; 87–104. 92 Allard M, Doucet D, Kien P, Bonnemain B, Caillë JM Experimental study of DOTA-gadolinium: pharmacokinetics and pharmacologic properties. Invest Radiol 1988; 23 (suppl): S271–S274. 93 Katzberg RW, Sahler LG, Duda SW, et al. Renal handling and physiologic effects of the paramagnetic contrast medium Gd-DOTA. Invest Radiol 1990; 25: 714–719. 94 Tweedle MF, Gaughan GT, Hagan JH 1-substituted- 1,4,7-triscarboxymethyl-1,4,7,10,-tetraazacyclododecane and analogs. U.S. patent 4,885,363, 1987. 95 Aime S, Botta M, Ermondi G, et al. Relationships between solution structures and relaxivities of paramagnetic Gd(III) chelates (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1989. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1989; 1152. 96 Tweedle MF, Gaughan GT, Brittain HG, Hagan JJ Gd(DO3A)(H2O), a neutral, water soluble complex useful in NMR imaging (abstr). Presented at the 194th American Chemical Society National Meeting, New Orleans, La, August 30-September 4, 1987. 97 Horrocks WD, Sudnick DR Lanthanide ion probes of structure in biology: laser-induced luminescence decay constants provide a direct measure of the number of metal-coordinated water molecules. J Am Chem Soc 1979; 101: 334–340. 98 Chang CA, Tweedle MF Preclinical studies with GdHP-DO3A. Presented at The Second European Workshop on Magnetic Resonance in Medicine, Bordeaux, France, September 26–28, 1991. 99 Gaughan G Nonionic gadolinium chelates. In: VM Runge, ed: Enhanced magnetic resonance imaging. St Louis, Mo: Mosby, 1989. 100 Eaton S, DeSimone D, Willard D, Zielonka J, Stouffer B, Eckelman W Human pharmacokinetics of Prohance (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1990. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1990; 728. 101 Carvlin M, Rosa L, Schellinger D, et al. Report on clinical trials of Prohance: efficacy and safety evaluation of a new low osmolar MR contrast medium (abstr). In: Book of abstracts: Society of Magnetic Resonance in Medicine 1990. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1990; 729. 102 Runge VM, Gelblum DY, Pacetti MI, Carolan FJ, Heard GG Clinical efficacy of Gd(HP-DO3A), a non-ionic gadolinium cryptelate (abstr). Magn Reson Imaging 1990; 8 (suppl 1): 47. 103 Delgado R, Fraústo da Silva JJR Metal complexes of cyclic tetra-azatetraacetic acids. Talanta 1982; 29: 815–822. 104 Amorim MTS, Delgado R, Fraústo da Silva JJR, Cândida M, Vaz TA, Fernanda Vilhena M Metal complexes of 1-oxa-4,7,10-triazacyclododecane-N, N', N'-triacetic acid. Talanta 1988; 35: 741–745. 105 De Cola L, Smailes DL, Vallarino LM Hexaaza macrocyclic complexes of the lanthanides. Inorg Chem 1986; 25: 1729–1732. 106 Sargeson AM Caged metal ions. Chem Br 1979; 16: 23–27. 107 Smith PH, Raymond KN A lanthanide-amine template synthesis: preparation and molecular structure of Ln(L)(CH3CN)-(CF3SO3)3 [L = 1,9-bis(2-aminoethyl)-1,4,6,9,12,14-hexa-azacyclohexadecane; Ln = La, Yb]and La(en)4(CH3CN)-(CF3SO3)3. Inorg Chem 1985; 24: 3469–3477. 108 Smith PH, Brainard JR, Morris DE, Jarvinen GD, Ryan RR Solution and solid-state characterization of europium and gadolinium Schiff base complexes and assessment of their potential as contrast agents in magnetic resonance imaging. J Am Chem Soc 1989; 111: 7437–7443. 109 Chen C, Cohen JS, Myers CE, Sohn M Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 1984; 168: 70–74. 110 Lyon RC, Faustino PJ, Cohen JS, et al. Tissue distribution and stability of metalloporphyrin MRI contrast agents. Magn Reson Med 1987; 4: 24–33. 111 Ogan MD, Revel D, Brasch RC Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging: a study of human carcinoma, lymphoma, and fibro-sarcoma in mice. Invest Radiol 1987; 22: 822–828. 112 Patronas NJ, Cohen JS, Knop RH, et al. Metalloporphyrin contrast agents for magnetic resonance imaging of human tumors in mice. Cancer Treat Rep 1986; 70: 391–394. 113 Helpern JA, Curtis JC, Hearshen D, Smith MB. Welch KMA Development of a pH-sensitive contrast agent for NMR 1H imaging. Magn Reson Med 1987; 5: 302–305. 114 Sessler JL, Murai T, Hemmi G A water-stable gadolinium (III) complex derived from a new postadentate "expanded porphyrin" ligand. Inorg Chem 1989; 28: 3390–3393. 115 Leroy-Willig A, Duron A, Malgouyres A, Tavitian B, Syrota A Dynamic imaging of brain perfusion using Gd-DOTA at 0.5 T. In: Book of abstracts: Society of Magnetic Resonance in Medicine 1992. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1992; 1137. Citing Literature Volume3, Issue1Special Issue: Contrast AgentsJanuary/February 1993Pages 167-178 ReferencesRelatedInformation